Next 10 |
2024-04-21 06:46:42 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
STARMAP ( S tudy T reating A cquired R esistance: M APK A m p lifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer therapies BBI-825 is a novel, oral, selective ribonucleotide redu...
Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled oncogene amplified cancers Third poster presentation to highlight the potential role of ...
2024-03-30 01:00:00 ET Summary Three IPOs and one SPAC debuted this past week, while three IPOs submitted initial filings - Boundless Bio, U-BX Technology, Alta Global, and IB Acquisition, respectively. Three IPOs submitted initial filings this week - Marex Group, Reitar Logtech a...
2024-03-28 13:51:03 ET More on Boundless Bio, Inc., Renaissance Capital Greenwich Funds - Renaissance IPO ETF, etc. Read the full article on Seeking Alpha For further details see: Bayer-backed Boundless Bio stock down 8% after $100M IPO
Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 ...
Natural gas has been one of the worst-performing commodities over the last decade. However, the fundamentals are improving due to demand improving, and production being depressed. Reason one- Georgia will determine US energy policy Reason two- The rig count is low while the dema...
Satsuma Pharmaceuticals ( STSA -0.3% ) appointed industry veteran Thomas M. Soloway, currently serving as EVP and COO of Audentes Therapeutics ( BOLD ), to its board of directors, effective July 2, 2020. More news on: Satsuma Pharmaceuticals, Inc., Audentes Therapeutics, Inc., Asc...
Broadly, genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So what is genetics investing? When it comes to genetics investing, companies in this niche li...
We've run through 10 different sectors or styles of investing in our year-end Marketplace Roundtable series. You can review the full list of roundtables at the end of this article in case you'd like to catch up on any specific angle. As we do every year, we conclude the series with the com...
News, Short Squeeze, Breakout and More Instantly...
Audentes Therapeutics Inc. Company Name:
BOLD Stock Symbol:
NASDAQ Market:
Audentes Therapeutics Inc. Website:
STARMAP ( S tudy T reating A cquired R esistance: M APK A m p lifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer therapies BBI-825 is a novel, oral, selective ribonucleotide redu...
Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled oncogene amplified cancers Third poster presentation to highlight the potential role of ...
Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 ...